Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Abstract
Abstracts
Addendum
Brief Communication
Case Report
Case Series
Commentary
Conference Abstract
Conference Editorial
Conference Proceedings
Current Issue
Editorial
Editorial Commentary
Erratum
General Medicine Original Article
General Medicine, Case Report
General Medicine, Review Article
IAPCONKochi 2019 Conference Proceedings
Letter to Editor
Letter to the Editor
Letters to Editor
Media & News
Narrative Review
Notice of Retraction
Oral Abstracts
Original Article
Palliative Medicine Commentary
Palliative Medicine, Letter to Editor
Palliative Medicine, Letter to the Editor
Palliative Medicine, Original Article
Palliative Medicine, Review Article
Personal Reflection
Perspective
Perspectives
Position Paper
Position Statement
Poster Abstracts
Practitioner Section
Report
REPUBLICATION: Special Article (Guidelines)
Retraction
Review Article
Reviewers 2023
Short Communication
Short Report
Special Editorial
Special Review
Systematic Review
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Abstract
Abstracts
Addendum
Brief Communication
Case Report
Case Series
Commentary
Conference Abstract
Conference Editorial
Conference Proceedings
Current Issue
Editorial
Editorial Commentary
Erratum
General Medicine Original Article
General Medicine, Case Report
General Medicine, Review Article
IAPCONKochi 2019 Conference Proceedings
Letter to Editor
Letter to the Editor
Letters to Editor
Media & News
Narrative Review
Notice of Retraction
Oral Abstracts
Original Article
Palliative Medicine Commentary
Palliative Medicine, Letter to Editor
Palliative Medicine, Letter to the Editor
Palliative Medicine, Original Article
Palliative Medicine, Review Article
Personal Reflection
Perspective
Perspectives
Position Paper
Position Statement
Poster Abstracts
Practitioner Section
Report
REPUBLICATION: Special Article (Guidelines)
Retraction
Review Article
Reviewers 2023
Short Communication
Short Report
Special Editorial
Special Review
Systematic Review
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Abstract
Abstracts
Addendum
Brief Communication
Case Report
Case Series
Commentary
Conference Abstract
Conference Editorial
Conference Proceedings
Current Issue
Editorial
Editorial Commentary
Erratum
General Medicine Original Article
General Medicine, Case Report
General Medicine, Review Article
IAPCONKochi 2019 Conference Proceedings
Letter to Editor
Letter to the Editor
Letters to Editor
Media & News
Narrative Review
Notice of Retraction
Oral Abstracts
Original Article
Palliative Medicine Commentary
Palliative Medicine, Letter to Editor
Palliative Medicine, Letter to the Editor
Palliative Medicine, Original Article
Palliative Medicine, Review Article
Personal Reflection
Perspective
Perspectives
Position Paper
Position Statement
Poster Abstracts
Practitioner Section
Report
REPUBLICATION: Special Article (Guidelines)
Retraction
Review Article
Reviewers 2023
Short Communication
Short Report
Special Editorial
Special Review
Systematic Review
View/Download PDF

Translate this page into:

Letters to Editor
24 (
3
); 384-385
doi:
10.4103/IJPC.IJPC_208_17

Tanezumab: Finally a Monoclonal Antibody for Pain Relief

Department of Anaesthesiology, Basavatarakam Indo-American Cancer Hospital and Research Institute, Hyderabad, Telangana, India

Address for correspondence: Dr. Abhijit S Nair, Department of Anaesthesiology, Basavatarakam Indo-American Cancer Hospital and Research Institute, Hyderabad - 500 034, Telangana, India. E-mail: abhijitnair95@gmail.com

Licence

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Disclaimer:
This article was originally published by Medknow Publications & Media Pvt Ltd and was migrated to Scientific Scholar after the change of Publisher.

Sir,

Nerve growth factor (NGF) is a neurotrophin that promotes the growth and differentiation of sensory and sympathetic ganglia. Inflammation and peripheral nerve injury lead to increased levels of NGF. NGF is also increased in all chronic nociceptive and neuropathic pain states which include all types of cancer and noncancer pain. NGF is produced as a response to any noxious stimuli that produce inflammatory cytokines such as interleukin-1 and tumor necrosis factor alpha.[1]

NGF binds to tropomyosin-related kinase A (trkA) which is expressed on the A-delta and C-fibers. NGF also binds to trkA on mast cells and releases histamine, serotonin, protons, and thereby starts a vicious cycle of inflammation.

Tanezumab is a humanized monoclonal IgG2 antibody that blocks NGF from activating trkA receptors on nociceptive neurons. The inhibition of NGF in acute and chronic painful states is a novel mechanism of action, unlike opioids and nonsteroidal anti-inflammatory drugs (NSAIDs). By inhibiting NGF, tanezumab interferes with pain signals produced by muscles, skin, and organs from reaching the spinal cord and brain. Clinical trials with tanezumab started in 2009 with doses of 10, 25, 50, 100, or 200 μg/kg on day 1 and day 56 (8 weeks).[2] However, in one of the Phase III trials, 16 patients required hip replacement which was thought due to rapidly progressing osteoarthritis and radiologically evident bone necrosis due to the drug. This brought a halt to the trial in June 2010 due to not clearly defined safe dose of tanezumab (https://www.clinicaltrials.gov/show/NCT00744471).

The drug was later studied extensively with close monitoring of adverse effects. Randomized, double-blind, placebo-controlled Phase III trial by Brown et al. compared tanezumab with placebo and found tanezumab to be superior in providing pain relief and improvement in physical function versus placebo in patients with painful hip arthritis.[3] The authors used 2.5 mg, 5 mg, and 10 mg of tanezumab IV every 8 weeks for 24 weeks versus trkA placebo. Paresthesia and hypoesthesia were common adverse effects in all groups while some patients also had neuropathy, peripheral edema, upper respiratory tract infection, pain in extremity, arthralgia, urinary tract infection, and headache more common in patients who received 10 mg dose. The study showed that the dose of 5 mg and 10 mg had good response compared to 2.5 mg but 10 mg group had the highest incidence of adverse events. In neuropathic pain, the levels of NGF and severity of pathology are complex. Bramson et al. evaluated efficacy and safety of tanezumab in two neuropathic pain conditions: diabetic peripheral neuropathy (DPN) and postherpetic neuralgia (PHN) with placebo in each condition.[4] They observed that tanezumab was effective in DPN, but in PHN, even the maximum dose of 200 μg/kg every 8 weeks was not very effective. The reason for this could be the different pathology leading to neuropathic pain in both syndromes. In diabetes, there is length-dependent neuropathy, i.e., the longest axons in peripheral nerve are affected which involves small fibers. In PHN, the peripheral nerve is damaged due to herpes zoster infection due to which pain is along the affected dermatomes.[5]

U. S. food and drug administration has granted fast track designation for tanezumab in patients with osteoarthritis and chronic low back pain who are refractory to conventional medications (https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-lilly-receive-fda-fast-track-designation-for-tanezumab). The advantages are single injection every 8 weeks with minimal adverse effects. However, the cost of medication could be the limiting factor for its use. However, the drug is devoid of adverse effects such as constipation, respiratory depression, tolerance, and dependence like with opioids and has no cardiovascular or renal toxicity as observed with NSAIDs. Moreover, the dose comes once in 56 days or 8 weeks.

Tanezumab has equivocal efficacy when administered subcutaneously. This could reduce the cost further as injection can be taken by the patient at home without visiting the hospital or health-care provider.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

REFERENCES

  1. , , , , , , . Anti-nerve growth factor in the treatment of low back pain and radiculopathy: A systematic review and a meta-analysis. Pain Physician. 2014;17:E45-60.
    [Google Scholar]
  2. , , , , , , . Tanezumab for the treatment of pain from osteoarthritis of the knee. N Engl J Med. 2010;363:1521-31.
    [Google Scholar]
  3. , , , , , , . Tanezumab reduces osteoarthritic hip pain: Results of a randomized, double-blind, placebo-controlled phase III trial. Arthritis Rheum. 2013;65:1795-803.
    [Google Scholar]
  4. , , , , , , . Exploring the role of tanezumab as a novel treatment for the relief of neuropathic pain. Pain Med. 2015;16:1163-76.
    [Google Scholar]
  5. , , . Mechanisms of neuropathic pain. Neuron. 2006;52:77-92.
    [Google Scholar]
Show Sections